Clinical Trial Update: A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) [Phase 3]

View source ↗

Summary

A Phase 3 trial (TRAILBLAZER-ALZ 4) comparing donanemab with aducanumab in early symptomatic Alzheimer's disease has completed, with results posted in November …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Aducanumab (aducanumab)
• Donanemab (donanemab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Mild Cognitive Impairment (MCI), Alzheimer Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-11-02